BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33780623)

  • 21. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.
    Zhao P; Zhuang L; Wang X; Huang S; Wu H; Zhou Y; Yan Y; Zhang F; Shen R; Li J; Liu S; Zhang R; Dong P; Mao Y; Fan Y; He C; Sun J; Zhang L; Hu Q; Wan H; Feng J; Bai C; He F; Tao W
    Eur J Med Chem; 2022 Jan; 228():114040. PubMed ID: 34906761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer.
    Cheng Y; Wang X; Xia X; Zhang W; Tian H
    Int J Cancer; 2019 Jul; 145(2):586-596. PubMed ID: 30628057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
    Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
    Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
    Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
    Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
    J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
    Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
    Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
    King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
    Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
    Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
    PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Setting up a kinase discovery and development project.
    Bollag G
    Curr Top Microbiol Immunol; 2012; 355():3-18. PubMed ID: 21809194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
    El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
    Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
    Jones GG; Del Río IB; Sari S; Sekerim A; Young LC; Hartig N; Areso Zubiaur I; El-Bahrawy MA; Hynds RE; Lei W; Molina-Arcas M; Downward J; Rodriguez-Viciana P
    Nat Commun; 2019 Jun; 10(1):2532. PubMed ID: 31182717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
    Wang Z; Yin M; Chu P; Lou M
    Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
    Sini P; Gürtler U; Zahn SK; Baumann C; Rudolph D; Baumgartinger R; Strauss E; Haslinger C; Tontsch-Grunt U; Waizenegger IC; Solca F; Bader G; Zoephel A; Treu M; Reiser U; Garin-Chesa P; Boehmelt G; Kraut N; Quant J; Adolf GR
    Mol Cancer Ther; 2016 Oct; 15(10):2388-2398. PubMed ID: 27496137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.